top of page
Search


New screening tool amplifies detection of protein changes
Catalyst innovators have developed a high-throughput method which enables researchers to screen hundreds of drugs in parallel, accelerating discovery of therapies that degrade disease-causing proteins. Read the full article on the Stanford Report at https://news.stanford.edu/stories/2026/09/chemistry-tool-protein-changes-detection.
Sep 22


Stanford Medicine Catalyst Welcomes Newest Award Recipients
Stanford Medicine Catalyst is pleased to announce and welcome five new Catalyst Award recipients. Congratulations to the project teams for each of these exciting projects – spanning medical devices and diagnostics, digital health and therapeutics – which hold the promise and potential to transform and significantly impact global health care.
Aug 21


Supercharged natural killer cells suppress solid tumors in mice
By Nina Bai Read the full article on the Stanford Medicine News Center. Scientists have made great progress in harnessing the body’s own immune cells to treat so-called liquid tumors, cancers of the blood and lymphatic system. Yet these powerful cell therapies have been no match for solid tumors, which are tough to access and secrete signals that can stifle immune cells that get too close. In a new study, Stanford Medicine researchers and collaborators report making inroads o
Jun 29


Catalyst accelerates SWIFT Bio's path to ultra-rapid genomic diagnostics in critical care
At Stanford Medicine, Catalyst accelerates bold innovations with funding, incubation support, network connections, and more to drive real-world, global impact. Swift Bio joined Catalyst in May 2024 as one such venture. Photo caption: SWIFT Bio’s leaders John Gorzynski, DVM, PhD, and Sneha Goenka, PhD, with Euan Ashley, MD, PhD at the Ashley Lab. Led by Chief Scientific Officer, John Gorzynski, DVM, PhD (Stanford ’21) and Chief Executive Officer, Alex Johnson, Swift Bio is an
Mar 11


How a pacemaker for the brain is helping Parkinson’s patients | CNN
Catalyst Innovator Dr. Helen Bronte-Stewart, a Stanford Medicine professor of neurology, has dedicated her career to understanding how the brain controls movement and what happens when that process breaks down. As the global lead investigator of an international clinical trial, she spearheaded the development of an adaptive deep brain stimulation (aDBS) device — essentially a pacemaker for the brain — that senses brain activity in real time and tailors electrical pulses accor
Mar 3


Catalyst featured in Stanford Medicine Magazine
Five years is not a long time in health care innovations. It takes, on average, 10 to 15 years to bring a new drug to market and three to seven years for new medical devices. And that’s if you have the funding and know what you’re doing. More often than not, medical innovations tumble into the ”valley of death” between bench and bedside, never crossing from initial scientific discovery to commercial product and patient care. Five years ago, Susan Hiniker , MD, an associate pr
Mar 2
bottom of page